Targeting hexokinase II to mitochondria to modulate energy metabolism and reduce ischaemia-reperfusion injury in heart

British Journal of Pharmacology

Volumn 171, Issue 8, 2014, Pages 2067-2079

  Nederlof, Rianne ^a   Eerbeek, Otto ^a   Hollmann, Markus W ^a   Southworth, Richard ^b   Zuurbier, Coert J ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

cell death; diabetes; glycolysis; ischaemia reperfusion injury; mitochondria; mPTP

Indexed keywords

HEXOKINASE; CARDIOTONIC AGENT;

ENERGY METABOLISM; HUMAN; MITOCHONDRION; PRIORITY JOURNAL; REPERFUSION INJURY; REVIEW; DRUG EFFECTS; ENZYMOLOGY; HEART DISEASES; METABOLISM; MOLECULARLY TARGETED THERAPY; MYOCARDIAL REPERFUSION INJURY; NEOPLASM; PATHOPHYSIOLOGY; PHYSIOLOGY; PROCEDURES;

CARDIOTONIC AGENTS; ENERGY METABOLISM; HEART DISEASES; HEXOKINASE; HUMANS; MITOCHONDRIA; MOLECULAR TARGETED THERAPY; MYOCARDIAL REPERFUSION INJURY; NEOPLASMS;

EID: 84897425087     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12363     Document Type: Review

References (132)

1. Abraham S, Borrebaeck B, Chaikoff IL, (1964). Effect of dietary carbohydrates on glucokinase and mannokinase activities of various rat tissues. J Nutr 83: 273-288.
2. Ahmad A, Ahmad S, Schneider BK, Allen CB, Chang L-Y, White CW, (2002). Elevated expression of hexokinase II protects human lung epithelial-like A549 cells against oxidative injury. Am J Physiol Lung Cell Mol Physiol 283: L573-L584.
3. Atherton HJ, Dodd MS, Heather LC, Schroeder MA, Griffin JL, Radda JL, et al. (2011). Role of pyruvate dehydrogenase inhibition in the development of hypertrophy in the hyperthyroid rat heart: a combined magnetic resonance imaging and hyperpolorized magnetic resonance spectroscopy study. Circulation 123: 2552-2561.
4. Bernardi P, (1992). Modulation of the mitochondrial cyclosporin A-sensitive permeability transition pore by the proton electrochemical gradient. J Biol Chem 267: 8834-8839.
5. Bessmann SP, Geiger PJ, (1980). Compartmentation of hexokinase and creatine kinase phosphokinase, cellular regulation, and insulin action. In:, Horecker BL, Stadtman ER, (eds). Current Topics in Cellular Regulation, Vol. 16. Academic: New York, pp. 55-86.
6. Beutner G, Ruck A, Riede B, Brdiczka D, (1998). Complexes between porin, hexokinase, mitochondrial creatine kinase and adenylate translocator display properties of the permeability transition pore. Implications for regulation of permeability transition by the kinases. Biochim Biophys Acta 1368: 7-18.
7. Bhamra GS, Hausenloy DJ, Davidson SM, Carr RD, Paiva M, Wynne AM, et al. (2008). Metformin protects the ischemic heart by the Akt-mediated inhibition of mitochondrial permeability transition pore opening. Basic Res Cardiol 103: 274-284.
8. Birsoy K, Wang T, Possemato R, Yilmaz OH, Koch CE, Chen WW, et al. (2013). MCT1-mediated transport of a toxic molecule is an effective strategy for targeting glycolytic tumors. Nat Gen 45: 104-108.
9. Bonnet S, Archer SL, Allalunis-Turner J, Haromy A, Beaulieu C, Thompson R, et al. (2007). A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. Cancer Cell 11: 37-51.
10. Brdiczka D, (1990). Interaction of mitochondrial porin with cytosolic proteins. Experientia 46: 161-167.
11. Brdiczka DG, Zorov DB, Sheu SS, (2006). Mitochondrial contact sites: their role in energy metabolism and apoptosis. Biochim Biophys Acta 1762: 148-163.
12. Bryson JM, Coy PE, Gottlob K, Hay N, Robey RB, (2002). Increased hexokinase expression of either ectopic or endogenous origin, protects renal epithelial cells against acute oxidant-induced cell death. J Biol Chem 277: 11392-11400.
13. Bustamante E, Pedersen PL, (1977). High aerobic glycolysis of rat hepatoma cells in culture: role of mitochondrial hexokinase. Proc Natl Acad Sci U S A 74: 3735-3739.
14. Bustamante E, Morris HP, Pedersen PL, (1981). Energy metabolism of tumor cells. Requirements for a form of hexokinase with a propensity for mitochondrial binding. J Biol Chem 256: 8699-8704.
15. Calvert JW, Gundewar S, Jha S, Greer JJ, Bestermann WH, Tian R, et al. (2008). Acute metformin therapy confers cardioprotection against myocardial infarction via AMPK-eNOS-mediated signaling. Diabetes 57: 696-705.
16. Chae YC, Caino MC, Lisanti S, Ghosh JC, Dohi T, Danial NN, et al. (2012). Control of tumor bioenergetics and survival stress signalling by mitochondrial HSP90s. Cancer Cell 22: 331-344.
17. Chen LB, (1988). Mitochondrial membrane potential in living cells. Annu Rev Cell Biol 4: 155-181.
18. Chiara F, Castellaro D, Marin O, Petronilli V, Brusilow WS, Juhaszova M, et al. (2008). Hexokinase II detachment from mitochondria triggers apoptosis through the permeability transition pore independent of voltage-dependent anion channels. PLoS ONE 3: e1852.
19. Colombini M, (2004). VDAC: the channel at the interface between mitochondria and the cytosol. Mol Cell Biochem 256-257: 107-115.
20. Corona JC, Gimenez-Cassina A, Lim F, Diaz-Nido J, (2010). Hexokinase II gene transfer protects against neurodegeneration in the rotenone and MPTP mouse models of Parkinson's disease. J Neurosci Res 88: 1943-1950.
21. Correa F, Garcia N, Gallardo-Perez JC, Carreno-Fuentes L, Rodrigues-Enriques S, Marin-Hernandez A, et al. (2008). Post-conditioning preserves glycolytic ATP during early reperfusion: a survival mechanism for the reperfused heart. Cell Physiol Biochem 22: 635-644.
22. Crane RK, Sols A, (1953). The association of hexokinase with particulate fractions of brain and other tissue hoogenates. J Biol Chem 203: 273-292.
23. Da Silva D, Ausina P, Alencar EM, Coelho WS, Zancan P, Sola-Penna M, (2012). Metformin reverses hexokinase and phosphofructokinase downregulation and intracellular distribution in the heart of diabetic mice. IUBMB Life 64: 766-774.
24. Da-Silva WS, Gomez-Puyou A, de Gomez-Puyou MT, Moreno-Sanchez R, de Felice FG, de Meis L, et al. (2004). Mitochondrial bound hexokinase activity as a preventive antioxidant defense: steady-state ADP formation as a regulatory mechanism of membrane potential and reactive species generation in mitochondria. J Biol Chem 279: 39846-39855.
25. De Hert SG, (2011). Cardioprotection by volatile anesthetics: what about noncardiac surgery? J Cardiothorac Vasc Anesth 25: 899-901.
26. De Jong JW, Hülsmann WC, (1970). Effects of nagarse, adenosine and hexokinase on palmitate activation and oxidation. Biochim Biophys Acta 210: 499-501.
27. Dieni CA, Storey KB, (2011). Regulation of hexokinase by reversible phosphorylation in skeletal muscle of a freeze-tolerant frog. Comp Biochem Physiol B Biochem Mol Biol 159: 236-243.
28. El Messaoudi S, Rongen GA, Riksen NP, (2013). Metformin therapy in diabetes: the role of cardioprotection. Curr Atheroscler Rep 15: 314.
29. Fiek C, Benz R, Roos N, Brdiczka D, (1982). Evidence for identity between the hexokinase-binding protein and the mitochondrial porin in the outer membrane of rat liver mitochondria. Biochim Biophys Acta 688: 429-440.
30. Forte M, Adelsberger-Mangan D, Colombini M, (1987). Purification and characterization of the voltage-dependent anion channel from the other mitochondrial membrane of yeast. J Membr Biol 99: 65-72.
31. Furuta H, Nishi S, Le Beau MML, Fernald AA, Yano H, Bell GI, (1996). Sequence of human hexokinase III cDNA and assignment of the human hexokinase III gene (HK3) to chromosome band 5q35.2 by fluorescence in situ hybridization. Genomics 36: 206-209.
32. Gall JM, Wong V, Pimental DR, Havasi A, Wang Z, Pastorino JG, et al. (2011). Hexokinase regulates Bax-mediated mitochondrial membrane injury following ischemic stress. Kidney Int 79: 1207-1216.
33. Gimenez-Cassina A, Lim F, Palomo GM, Diaz-Nido J, (2009). Mitochondrial hexokinase II promotes neuronal survival and acts downstream of glycogen synthase kinase-3. J Biol Chem 284: 3001-3011.
34. Giorgio V, von Stockum S, Antoniel M, Fabbro A, Fogolari F, Forte M, et al. (2013). Dimers of mitochondrial ATP synthase form the permeability transition pore. Proc Natl Acad Sci U S A 110: 5887-5892.
35. Goldin N, Arzoine L, Heyfets A, Israelson A, Zaslavsky Z, Bravman T, et al. (2008). Methyl jasmonate binds to and detaches mitochondria-bound hexokinase. Oncogene 27: 4636-4643.
36. Gottlob K, Majewski N, Kennedy S, Kandel E, Robey RB, Hay N, (2001). Inhibition of early apoptosis events by Akt/PKB is dependent on the first committed step of glycolysis and mitochondrial hexokinase. Genes Dev 15: 1406-1418.
37. Groen AK, Wanders RJA, Westerhoff HV, van der Meer R, Tager JM, (1982). Quantification of the contribution of various steps to the control of mitochondrial respiration. J Biol Chem 257: 2754-2757.
38. Gürel E, Smeele KM, Eerbeek O, Koeman A, Demirci C, Hollmann MW, et al. (2009). Ischemic preconditioning affects hexokinase activity and HKII in different subcellular compartments throughout cardiac ischemia-reperfusion. J Appl Physiol 106: 1909-1916.
39. Gürel E, Ustunova S, Kapucu A, Yilmazer N, Eerbeek O, Nederlof R, et al. (2013). Hexokinase cellular trafficking in ischemia-reperfusion and ischemic preconditioning is altered in type I diabetic heart. Mol Biol Rep 40: 4153-4160.
40. Halestrap A, (2009). What is the mitochondrial permeability transition pore? J Mol Cell Cardiol 46: 821-831.
41. Harrison GJ, Van Wijhe MH, de Groot B, Dijk FJ, Gustafson LA, van Beek JH, (2003). Glycolytic buffering affects cardiac bioenergetic signaling and contractile reserve similar to creatine kinase. Am J Physiol Heart Circ Physiol 285: H883-H890.
42. Hausenloy D, Tseng A, Mocanu MM, Yellon DM, (2005). Ischemic preconditioning protects by activating prosurvival kinases at reperfusion. Am J Physiol Heart Circ Physiol 288: H971-H976.
43. Heikkinen S, Suppola S, Malkki M, Deeb SS, Jänne J, Laakso M, (2000). Mouse hexokinase II gene: structure, cDNA, promotor analysis, and expression pattern. Mamm Genome 11: 91-96.
44. Heumann S, Falkenberg F, Pfleiderer G, (1974). Purification and immunological characterization of the human hexokinase isozymes I and III (ATP-D-hexose 6-phosphotransferase EC 2.7.1.1). Biochim Biophys Acta 334: 328-342.
45. Holmes BF, Kurth-Kraczek EJ, Winder WW, (1999). Chronic activation of 5′-AMP-activated protein kinase increases GLUT-4, hexokinase, and glycogen in muscle. J Appl Physiol 87: 1990-1995.
46. Jennings RB, (2013). Historical perspective on the pathology of myocardial ischemia/reperfusion injury. Circ Res 113: 428-438.
47. Jiang S, Zhang LF, Zhang HW, Hu S, Lu MH, Liang S, et al. (2012). A novel miR-155/miR-143 cascade controls glycolysis by regulating hexokinase 2 in breast cancer cells. EMBO J 31: 1985-1998.
48. John S, Weiss JN, Ribalet B, (2011). Subcellular localization of hexokinase I and II directs the metabolic fate of glucose. PLoS ONE 6: e17674.
49. Johnson MK, (1960). The intracellular distribution of glycolytic and other enzymes in rat brain homogenates and mitochondrial preparations. Biochem J 77: 610-618.
50. Juhaszova M, Zorov DB, Kim SH, Pepe S, Fu Q, Fishbein KW, et al. (2004). Glycogen synthase kinase-3beta mediates convergence of protection signaling to inhibit the mitochondrial permeability transition pore. J Clin Invest 113: 1535-1549.
51. Katzen HM, Soderman DD, Wiley CE, (1970). Multiple forms of hexokinase. Activities associated with subcellular particulate and soluble fractions of normal and streptozotocin diabetic rat tissues. J Biol Chem 245: 4081-4096.
52. Keith B, Johnson RS, Simon MC, (2012). HIF1α and HIF2α: sibling rivalry in hypoxic tumour growth and progression. Nat Rev Cancer 12: 9-22.
53. Ko YH, Verhoeven HA, Lee MJ, Corbin DJ, Vogl TJ, Pedersen PL, (2012). A translational study 'case report' on the small molecule 'energy blocker' 3-bromopyruvate (3BP) as a potent anticancer agent: from bench side to bedside. J Bioenerg Biomembr 44: 163-170.
54. Kottenberg E, Thielmann M, Bergmann L, Heine T, Jakob H, Heusch G, et al. (2012). Protection by remote ischemic preconditioning during coronary artery bypass graft surgery with isoflurane but not propofol-A clinical trial. Acta Anaesthesiol Scand 56: 30-38.
55. Latchman DS, (2001). Heat shock proteins and cardiac protection. Cardiovasc Res 51: 637-646.
56. Leung AW, Halestrap A, (2008). Recent progress in elucidating the molecular mechanism of the mitochondrial permeability transition pore. Biochim Biophys Acta 1777: 946-952.
57. Leung AW, Varanyuwatana P, Halestrap AP, (2008). The mitochondrial phosphate carrier interacts with cyclophilin D and may play a key role in the permeability transition. J Biol Chem 283: 26312-26323.
58. Li J, Xuan W, Yan R, Tropak MB, Jean-St-Michel E, Liang W, et al. (2011). Remote preconditioning provides potent cardioprotection via PI3K/Akt activation and is associated with nuclear accumulation of β-catenin. Clin Sci 120: 451-462.
59. Lionetti V, Aquaro GD, Simioniuc A, di Cristofano C, Forini F, Cecchetti F, et al. (2009). Severe mechanical dyssynchrony causes regional hibernation-like changes in pigs with nonischemic heart failure. J Cardiac Fail 15: 920-928.
60. Lyon AR, Joudrey PJ, Jin D, Nass RD, Aon MA, O'Rourke B, et al. (2010). Optical imaging of mitochondrial function uncovers actively propagating waves of mitochondrial membrane potential collapse across intact heart. J Mol Cell Cardiol 49: 565-575.
61. McFalls EO, Murad B, Liow JS, Gannon MC, Haspel HC, Lange A, et al. (2002). Glucose uptake and glycogen levels are increased in pig heart after repetitive ischemia. Am J Physiol Heart Circ Physiol 282: H205-H211.
62. McMurtry MS, Bonnet S, Wu X, Dyck JR, Haromy A, Hashimoto K, et al. (2004). Dichloroacetate prevents and reverses pulmonary hypertension by inducing pulmonary artery smooth muscle cell apoptosis. Circ Res 95: 830-840.
63. Majewski N, Nogueira V, Bhaskar P, Coy PE, Skeen JE, Gottlob K, et al. (2004). Hexokinase-mitochondria interaction mediated by Akt is required to inhibit apoptosis in the presence or absence of Bax and Bak. Mol Cell 16: 819-830.
64. Mandarino LJ, Printz RL, Cusi KA, Kinchington P, O'Doherty R, Osawa H, et al. (1995). Regulation of hexokinase II and glycogen synthase mRNA, protein, and activity in human muscle. Am J Physiol 269: E701-E708.
65. Marzo I, Brenner C, Zamzami N, Susin SA, Beutner G, Brdiczka D, et al. (1998). The permeability transition pore complex: a target for apoptosis regulation by caspases and Bcl-2-related proteins. J Exp Med 187: 1261-1271.
66. Mathupala SP, Ko YH, Pedersen PL, (2009). Hexokinase-2 bound to mitochondria: cancer's stygian link to the 'Warburg effect' and a pivotal target for effective therapy. Semin Cancer Biol 19: 17-24.
67. Matkovich SJ, Hu Y, Dorn GW II, (2013). Regulation of cardiac microRNAs by cardiac microRNAs. Circ Res 113: 62-71.
68. Mergenthaler P, Kahl A, Kamitz A, van Laak V, Stohlmann K, Thomsen S, et al. (2012). Mitochondrial hexokinase II (HKII) and phosphoprotein enriched in astrocytes (PEA15) form a molecular switch governing cellular fate depending on the metabolic state. Proc Natl Acad Sci U S A 109: 1518-1523.
69. Michelakis ED, Sutendra G, Dromparis P, Webster L, Harmony A, Niven E, et al. (2010). Metabolic modulation of glioblastoma with dichloroacetate. Sci Transl Med 2: 31ra34.
70. Miki T, Itoh T, Sunaga D, Miura T, (2012). Effects of diabetes on myocardial infarct size and cardioprotection by preconditioning and postconditioning. Cardiovasc Diabetol 11: 67.
71. Miyamoto S, Murphy AN, Brown JH, (2008). Akt mediates mitochondrial protection in cardiomyocytes through phosphorylation of mitochondrial hexokinase-II Cell Death Differ 15: 521-529.
72. Miyamoto S, Purcell NH, Smith JM, Gao T, Whittaker R, Huang K, et al. (2010). PHLPP-1 negatively regulates Akt activity and survival in the heart. Circ Res 107: 476-484.
73. Murphy E, Steenbergen C, (2008). Mechanisms underlying acute protection from cardiac ischemia-reperfusion injury. Physiol Rev 88: 581-590.
74. Murry CE, Jennings RB, Reimer KA, (1986). Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 74: 1124-1136.
75. Nakashima RA, Mangan PS, Colombini M, Pedersen PL, (1986). Hexokinase receptor complex in hepatoma mitochondria: evidence from N,N'- dicyclohexylcarbodiimide-labeling studies for the involvement of the pore-forming protein VDAC. Biochemistry 25: 1015-1021.
76. Nederlof R, Xie C, Eerbeek O, Koeman A, Milstein DMJ, Hollmann MW, et al. (2013). Pathophysiological consequences of TAT-HKII peptide administration are independent of impaired vascular function and ensuing ischemia. Circ Res 112: e8-e13.
77. Ng KW, Allen ML, Desai A, Macrae D, Pathan N, (2012). Cardioprotective effects of insulin: how intensive insulin therapy may benefit cardiac surgery patients. Circulation 125: 721-728.
78. Ouyang J, Parakhia RA, Ochs RS, (2011). Metformin activates AMP kinase through inhibition of AMP deaminase. J Biol Chem 286: 1-11.
79. Owen MR, Doran E, Halestrap AP, (2000). Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem J 348: 607-614.
80. Pasdois P, Parker JC, Griffiths EJ, Halestrap AP, (2011). The role of oxidized cytochrome c in regulating mitochondrial reactive oxygen species production and its perturbation in ischaemia. Biochem J 436: 493-505.
81. Pasdois P, Parker JE, Halestrap AP, (2013). Extent of mitochondrial hexokinase II dissociation during ischemia correlates with mitochondrial cytochrome c release, reactive oxygen species production, and infarct size on reperfusion. J Am Heart Assoc 2: e005645.
82. Pastorino JG, Shulga N, Hoek JB, (2002). Mitochondrial binding of hexokinase II inhibits bax-induced cytochrome c release and apoptosis. J Biol Chem 277: 7610-7618.
83. Pastorino JG, Hoek JB, Shulga N, (2005). Activation of glycogen synthase kinase 3{beta} disrupts the binding of hexokinase iI to mitochondria by phosphorylating voltage-dependent anion channel and potentiates chemotherapy-induced cytotoxicity. Cancer Res 65: 10545-10554.
84. Pedersen PL, (2007). Warburg, me and hexokinase 2: multiple discoveries of key molecular events underlying one of cancers' most common phenotypes, the 'Warburg effect', i.e. elevated glycolysis in the presence of oxygen. J Bioenerg Biomembr 39: 211-222.
85. Penso J, Beitner R, (1998). Clotrimazole and bifonazole detach hexokinase from mitochondria of melanoma cells. Eur J Pharmacol 342: 113-117.
86. Perevoshchikova IV, Zorov SD, Kotova EA, Zorov DB, Antonenko YN, (2010). Hexokinase inhibits flux of fluorescently labeled ATP through mitochondrial outer membrane porin. FEBS Lett 584: 2397-2402.
87. Peschiaroli A, Giacobbe A, Formosa A, Markert EK, Bongiorno-Borbone L, Levine AJ, et al. (2012). miR-143 regulates hexokinase 2 expression in cancer cells. Oncogene 32: 797-802.
88. Postic C, Shiota M, Magnuson MA, (2001). Cell-specific roles of glucokinase in glucose metabolism. Recent Prog Horm Res 56: 195-217.
89. Rabuazzo AM, Patane G, Anello M, Piro S, Vigneri R, Purrello F, (1997). Hexokinase shift to mitochondria is associated with an increased sensitivity to glucose in rat pancreatic islets. Diabetes 46: 1148-1152.
90. Riehle C, Wende AR, Zaha VG, Pires KM, Wayment B, Olsen C, et al. (2011). PCG-1β deficiency accelerates the transition to heart failure in pressure overload hypertrophy. Circ Res 109: 783-793.
91. Roosimaa M, Pódramägi T, Kadaja L, Ruusalepp A, Paju K, Puhke R, et al. (2013). Dilation of human atria: increase diffusion restrictions for ADP, overexpression of hexokinase 2 and its coupling to oxidative phosphorylation in cardiomyocytes. Mitochondrion 13: 399-409.
92. Rostovtseva TK, Bezrukov SM, (2008). VDAC regulation: role of cytosolic proteins and mitochondrial lipids. J Bioenerg Biomembr 40: 163-170.
93. Rostovtseva TK, Tan W, Colombini M, (2005). On the role of VDAC in apoptosis: fact and fiction. J Bioenerg Biomembr 37: 129-142.
94. Rostovtseva TK, Sheldon KL, Hassanzadeh E, Monge C, Saks V, Bezrukov SM, et al. (2008). Tubulin binding blocks mitochondrial voltage-dependent anion channel and regulates respiration. Proc Natl Acad Sci U S A 105: 18746-18751.
95. Russell RR 3rd, Mrus JM, Mommessin JI, Taegtmeyer H, (1992). Compartmentation of hexokinase in rat heart. A critical factor for tracer kinetic analysis of myocardial glucose metabolism. J Clin Invest 90: 1972-1977.
96. Santiago AP, Chaves EA, Oliveira MF, Galina A, (2008). Reactive oxygen species generation is modulated by mitochondrial kinases: correlation with mitochondrial antioxidant peroxidises in rat tissues. Biochimie 90: 1566-1577.
97. Semenza GL, (2003). Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3: 721-732.
98. Sen S, Kundu BK, Wu HC, Hashmi SS, Guthrie P, Locke LW, et al. (2013). Glucose regulation of load-induced mTOR signalling and ER stress in mammalian heart. J Am Heart Assoc 2: e004796.
99. Sharma S, Adrogue JV, Golfman L, Uray I, Lemm J, Youker K, et al. (2004). Intramyocardial lipid accumulation in the failing human heart resembles the lipotoxic rat heart. FASEB J 18: 1692-1700.
100. Shaw RJ, Cantley LC, (2006). Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 441: 424-430.
101. Sheldon KL, Zuurbier CJ, Bezrukov SM, Rostovtseva TK, (2013). Novel mechanism of mitochondrial respiration control through competition between hexokinase-2 and tubulin for VDAC binding. Biophys J 104 (Suppl. 1): p655a.
102. Shioi T, McMullen JR, Tarnavski O, Concerso K, Sherwood MC, Manning WJ, et al. (2003). Rapamycin attenuates load-induced cardiac hypertrophy in mice. Circulation 107: 1664-1670.
103. Smeele KM, Eerbeek O, Koeman A, Bezemer R, Ince C, Heikkinen S, et al. (2010). Partial hexokinase II knockout results in acute ischemia-reperfusion damage in skeletal muscle of male, but not female, mice. Pflüg Arch 459: 705-712.
104. Smeele KM, ter Horst LH, Koeman A, Heikkinen S, Laakso M, Weber NC, et al. (2011b). The effect of standard chow and reduced hexokinase II on growth, cardiac and skeletal muscle hexokinase and low-flow cardiac ischaemia- reperfusion injury. Lab Anim 45: 160-166.
105. Smeele KM, Eerbeek O, Schaart G, Koeman A, Bezemer R, Nelson JK, et al. (2012). Reduced hexokinase II impairs muscle function 2 wk after ischemia-reperfusion through increased cell necrosis and fibrosis. J Appl Physiol 113: 608-618.
106. Smeele KMA, Southworth R, Wu R, Xie C, Nederlof R, Warley A, et al. (2011a). Disruption of hexokinase II-mitochondrial binding blocks ischemic preconditioning and causes rapid cardiac necrosis. Circ Res 108: 1165-1169.
107. Solskov L, Lofgren B, Kristiansen SB, Jessen N, Pold R, Nielsen TT, et al. (2008). Metformin induces cardioprotection against ischaemia/reperfusion injury in the rat heart 24 hours after administration. Basic Clin Pharmacol Toxicol 103: 82-87.
108. Southworth R, Davey KA, Warley A, Garlick PB, (2007). A reevaluation of the roles of hexokinase I and II in the heart. Am J Physiol Heart Circ Physiol 292: H378-H386.
109. Steenbergen C, Murphy E, Watts JA, London RE, (1990). Correlation between cytosolic free calcium, contracture, ATP, and irreversible ischemic injury in perfused rat heart. Circ Res 66: 135-146.
110. Suwa M, Egashira T, Nakano H, Sasaki H, Kumagai S, (2006). Metformin increases the PGC-1alpha protein and oxidative enzyme activities possibly via AMPK phosphorylation in skeletal muscle in vivo. J Appl Physiol 101: 1685-1692.
111. Terashima Y, Sato T, Yano T, Maas O, Itoh T, Miki T, et al. (2010). Role of phospho-GSK-3β in myocardial protection afforded by activation of the mitochondrial K ATP channel. J Mol Cell Cardiol 49: 762-770.
112. Thum T, (2011). MicroRNA therapeutics in cardiovascular medicine. EMBO Mol Med 4: 3-14.
113. Van Beek JHGM, Tian X, Zuurbier CJ, de Groot B, Van Echteld CJA, Eijgelshoven MHJ, et al. (1998). The dynamic regulation of myocardial oxidative phosphorylation: analysis of the response time of oxygen consumption. Mol Cell Biochem 184: 321-344.
114. Vestergaard H, Bjørbaek C, Hansen T, Larsen FS, Granner DK, Pedersen O, (1995). Impaired activity and gene expression of hexokinase II in muscle from non-insulin-dependent diabetes mellitus patients. J Clin Invest 96: 2639-2645.
115. Vytla VS, Ochs RS, (2013). Metformin increases mitochondrial energy formation in L6 muscle cell cultures. J Biol Chem 288: 20369-20377.
116. Warburg O, Posener K, Negelein E, (1924). Ueber den Stoffwechsel der Tumoren. Biochem Zeitschrift 152: 319-344.
117. Ward PS, Thompson CB, (2012). Metabolic reprogramming: a cancer hallmark even Warburg did not anticipate. Cancer Cell 21: 297-308.
118. Wei L, Zhou Y, Dai Q, Qiao C, Zhao L, Lu N, et al. (2013). Oroxylin A induces dissociation of hexokinase II from the mitochondria and inhibits glycolysis by SIRT3-mediated deacetylation of cyclophilin D in breast carcinoma. Cell Death Dis 4: e601. doi: 10.1038/cddis.2013.131.
119. Whittington HJ, Hall AR, McLaughlin CP, Hausenloy DJ, Yellon DM, Mocanu MM, (2013). Chronic metformin associated cardioprotection against infarction: not just a glucose lowering phenomenon. Cardiovasc Drugs Ther 27: 5-16.
120. Wilson JE, (1995). Hexokinases. Rev Physiol Biochem Pharmacol 126: 65-198.
121. Wilson JE, (2003). Isozymes of mammalian hexokinase: structure, subcellular localization and metabolic function. J Exp Biol 206: 2049-2057.
122. Wu R, Smeele KM, Wyatt E, Ichikawa Y, Eerbeek O, Sun L, et al. (2011). Reduction in hexokinase II levels results in decreased cardiac function and altered remodelling after ischemia-reperfusion injury. Circ Res 108: 60-69.
123. Wu R, Wyatt E, Chawla K, Tran M, Ghanefar M, Laakso M, et al. (2012). Hexokinase II knockdown results in exaggerated cardiac hypertrophy via increased ROS production. EMBO Mol Med 4: 633-646.
124. Xiang F, Huang YS, Shi XH, Zhang Q, (2010). Mitochondrial chaperone tumour necrosis factor receptor-associated protein 1 protects cardiomyocytes from hypoxic injury by regulating mitochondrial permeability transition pore opening. FEBS J 277: 1929-1938.
125. Yeih DF, Yeh HI, Lin LY, Tsay YG, Chiang FT, Tseng CD, et al. (2011). Enhanced activity and subcellular redistribution of myocardial hexokinase after acute myocardial infarction. Int J Cardiol 149: 74-79.
126. Zuurbier CJ, van Beek JHGM, (1997). Mitochondrial response to heart rate steps in isolated rabbit heart is slowed after myocardial stunning. Circ Res 81: 69-75.
127. Zuurbier CJ, Ince C, (2002). Post-ischaemic changes in the response time of oxygen consumption to demand in the isolated rat heart are mediated partly by calcium and glycolysis. Pflügers Arch 443: 908-916.
128. Zuurbier CJ, Eerbeek O, Goedhart PT, Struys EA, Verhoeven NM, Jakobs C, et al. (2004). Inhibition of the pentose phosphate pathway decreases ischemia-reperfusion-induced creatine kinase release in the heart. Cardiovasc Res 62: 145-153.
129. Zuurbier CJ, Eerbeek O, Meijer AJ, (2005). Ischemic preconditioning, insulin, and morphine all cause hexokinase redistribution. Am J Physiol Heart Circ Physiol 289: H496-H499.
130. Zuurbier CJ, Hoek FJ, van Dijk J, Abeling NG, Meijers JC, Levels JH, et al. (2008a). Perioperative hyperinsulinaemic normoglycaemic clamp causes hypolipidaemia after coronary artery surgery. Br J Anaesth 100: 442-450.
131. Zuurbier CJ, Keijzers PJM, Koeman A, van Wezel HB, Hollmann MW, (2008b). Anesthesia's effects on plasma glucose and insulin and cardiac hexokinase at similar hemodynamics and without major surgical stress in fed rats. Anesth Analg 106: 135-142.
132. Zuurbier CJ, Smeele KMA, Eerbeek O, (2009). Mitochondrial hexokinase and cardioprotection of the intact heart. J Bioenerg Biomembr 41: 181-185.